Kevin Dondarskit of Deloitte Consulting discusses the risks that drug makers face if they decide to put too much focus on an area where they may lack expertise, such as the emerging GLP-1 market. A ...
Makary’s departure followed internal disputes over approval decisions and Covid-19 vaccine posture, catalyzing a rapid ...
Transaction terms include an undisclosed upfront cash payment plus development milestones, for up to $202 million total consideration, with no additional financial details disclosed. Engage’s ...
Phase III Tropion‑Breast02 demonstrated a 43% reduction in progression/death risk versus chemotherapy, with median overall survival improved by five months in first-line metastatic TNBC. Objective ...
The Incyte–Genesis deal pairs significant upfront capital with long-tail milestones and royalties, while granting Incyte ...
Senators disclosed Taubenberger’s exit during a hearing after he failed to appear as a scheduled witness, and NIH leadership ...
In today's Pharmaceutical Executive Daily, Reuters reports that lower-priced oral GLP-1 pills from Eli Lilly and Novo Nordisk ...
This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...
A full clinical hold suspends dosing and enrollment in the Phase III HERO study and open-label extension, superseding the ...
Hypereosinophilic syndrome is defined by persistent eosinophilia with eosinophil-mediated organ/tissue damage, driving ...
In today's Pharmaceutical Executive Daily, Eli Lilly announces a deal worth up to $202 million for Engage Biologics and its ...
Regeneron and Parabilis Medicines partner to discover and develop antibody-Helicon conjugates, aiming to create a new class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results